Stockscreener 앱 받기
13.65
2.99%
-0.42
전일 마감가:
$14.07
열려 있는:
$14.07
하루 거래량:
3.69M
Relative Volume:
0.56
시가총액:
$2.54B
수익:
$93.95M
순이익/손실:
$-129.87M
주가수익비율:
-15.17
EPS:
-0.9
순현금흐름:
$-202.88M
1주 성능:
-1.37%
1개월 성능:
-16.82%
6개월 성능:
+74.55%
1년 성능:
+20.69%
1일 변동 폭
$13.59
$14.49
1주일 범위
$13.45
$15.97
52주 변동 폭
$5.28
$21.73
Wave Life Sciences Ltd Stock (WVE) Company Profile
명칭
Wave Life Sciences Ltd
전화
617-949-2900
주소
7 STRAITS VIEW, SINGAPORE
WVE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
WVE
Wave Life Sciences Ltd
|
13.65 | 2.61B | 93.95M | -129.87M | -202.88M | -0.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-12 | 재확인 | Wedbush | Outperform |
| 2025-12-09 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-10-20 | 개시 | Wells Fargo | Overweight |
| 2025-08-04 | 개시 | Canaccord Genuity | Buy |
| 2025-07-28 | 개시 | Oppenheimer | Outperform |
| 2025-07-16 | 개시 | Citigroup | Buy |
| 2025-06-11 | 재개 | Raymond James | Outperform |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-04-08 | 개시 | Wedbush | Outperform |
| 2025-02-25 | 개시 | Jefferies | Buy |
| 2024-10-16 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-09-27 | 재개 | JP Morgan | Overweight |
| 2024-09-19 | 개시 | B. Riley Securities | Buy |
| 2024-09-09 | 개시 | JP Morgan | Overweight |
| 2024-05-15 | 개시 | Wells Fargo | Overweight |
| 2023-12-19 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | 개시 | Raymond James | Outperform |
| 2023-05-24 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-12-15 | 재개 | H.C. Wainwright | Buy |
| 2020-10-23 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-12-31 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-11-01 | 개시 | Guggenheim | Buy |
| 2019-07-15 | 개시 | Cowen | Market Perform |
| 2019-04-17 | 재확인 | H.C. Wainwright | Buy |
| 2018-08-07 | 개시 | Stifel | Buy |
| 2018-07-23 | 개시 | H.C. Wainwright | Buy |
| 2018-03-19 | 재확인 | Mizuho | Buy |
| 2017-02-15 | 개시 | H.C. Wainwright | Buy |
| 2016-11-10 | 재개 | Leerink Partners | Outperform |
| 2015-12-07 | 개시 | JMP Securities | Mkt Outperform |
| 2015-12-07 | 개시 | Jefferies | Buy |
| 2015-12-07 | 개시 | Leerink Partners | Outperform |
| 2015-12-07 | 개시 | Sun Trust Rbsn Humphrey | Buy |
모두보기
Wave Life Sciences Ltd 주식(WVE)의 최신 뉴스
A Look At Wave Life Sciences (WVE) Valuation After WVE-007 Obesity Data And Development Update - simplywall.st
First Week of March 20th Options Trading For Wave Life Sciences (WVE) - Nasdaq
How Wave Life Sciences Ltd. (WVE) Affects Rotational Strategy Timing - Stock Traders Daily
Wave Life Sciences (WVE) Deepens Obesity Bet With WVE-007 Focus – Is Its Platform Strategy Evolving? - simplywall.st
WAVE Life Sciences (NASDAQ:WVE) Shares Up 6.8%Time to Buy? - MarketBeat
Truist Financial Maintains Wave Life Sciences(WVE.US) With Buy Rating - 富途牛牛
Wave Life Sciences (WVE) Receives a Buy from Raymond James - The Globe and Mail
Bull Bear: Will Wave Life Sciences Ltd stock recover faster than peersJuly 2025 Setups & Safe Entry Trade Signal Reports - moha.gov.vn
Wave Life Sciences Ltd. (WVE) Stock Analysis: A Biotech Gem With 129% Upside Potential - DirectorsTalk Interviews
Wave Life Sciences to expand obesity drug trials in 2026 By Investing.com - Investing.com Nigeria
Wave Life Sciences to expand obesity drug trials in 2026 - Investing.com
Wave Life Sciences sets 2026 strategy, highlights obesity program - TipRanks
Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing Portfolio - The Manila Times
An experimental RNA obesity treatment could allow once‑yearly dosing - Stock Titan
Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 for Obesity and Rapidly Advancing RNA Editing Portfolio - Investing News Network
WAVE Life Sciences (NASDAQ:WVE) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Wave Life Sciences stock drops 7% into JPM Healthcare Conference week — what to know next - TechStock²
Will Wave Life Sciences Ltd. stock maintain growth storyJuly 2025 Decliners & Expert Verified Movement Alerts - ulpravda.ru
Wave Life Sciences Ltd. (NASDAQ:WVE) May Have Run Too Fast Too Soon With Recent 30% Price Plummet - 富途牛牛
WAVE Life Sciences (NASDAQ:WVE) Shares Down 4.5%Here's Why - MarketBeat
Wave Life Sciences (WVE) stock slides 6% even as biotech ETFs rise — what’s driving it now - TechStock²
Wave Life Sciences (WVE) emerges as obesity treatment contender, Oppenheimer boosts price target - MSN
Wave Life Sciences upgraded at RBC following data for obesity asset WVE-007 - MSN
Is Wave Life Sciences Ltd. (1U5) stock protected from inflationEarnings Trend Report & Real-Time Market Sentiment Reports - ulpravda.ru
Aug Patterns: Will Wave Life Sciences Ltd. stock outperform tech sector in 2025CPI Data & Daily Entry Point Trade Alerts - ulpravda.ru
How Wave Life Sciences Ltd. (1U5) stock benefits from digital adoptionEarnings Summary Report & Safe Entry Momentum Stock Tips - ulpravda.ru
Quarterly Risk: Is Wave Life Sciences Ltd. stock dividend yield sustainableMarket Growth Summary & Safe Capital Allocation Plans - ulpravda.ru
What technical charts say about Wave Life Sciences Ltd. stock2025 Momentum Check & Accurate Trade Setup Notifications - ulpravda.ru
Will Wave Life Sciences Ltd. stock outperform tech sector in 2025July 2025 Trade Ideas & Step-by-Step Swing Trade Plans - ulpravda.ru
Wave Life Sciences (WVE) Valuation In Focus As Obesity Data, Equity Raise And Conference Updates Draw Attention - simplywall.st
Is Wave Life Sciences Ltd. stock attractive for income investorsPrice Channel Trading & Unlock Patterns Humans Can’t See - ulpravda.ru
Why Wave Life Sciences Ltd. stock is rated strong buyEx-Dividend Date Alerts & Use Smart Algorithms to Pick Better Stocks - ulpravda.ru
Raymond James raises WAVE Life Sciences stock price target to $26 By Investing.com - Investing.com South Africa
Raymond James raises WAVE Life Sciences stock price target to $26 - Investing.com India
Arrowhead siRNA data in obesity mark POC for adipose delivery - BioCentury
Is Wave Life Sciences’ (WVE) Obesity Bet and Extended Cash Runway Quietly Redefining Its Risk‑Reward Profile? - simplywall.st
HC Wainwright maintains a buy rating on Wave Life Sciences Ltd. (WVE) - MSN
Growth or Bubble? Decoding Wave Life Sciences’ Stock Rise - StocksToTrade
Wave Life Sciences stock gains after Arrowhead data supports INHBE mechanism - Investing.com UK
Wave Life Sciences (WVE) Sees Stock Rise Amid Positive Weight Lo - GuruFocus
Wave Life Sciences stock jumps 17% as obesity gene-silencing race heats up - TechStock²
WAVE Life Sciences (NASDAQ:WVE) Shares Gap UpWhat's Next? - MarketBeat
Wave Life Sciences (WVE) Rises Over 18% Following Market Activit - GuruFocus
Is Wave Life Sciences’ Stock a Hidden Gem? - timothysykes.com
Assessing Wave Life Sciences (WVE) Valuation After A Sharp Share Price Rebound - Yahoo Finance
Wave Life Sciences Ltd. (WVE) Stock Analysis: A Biotech Innovator with Over 110% Potential Upside - DirectorsTalk Interviews
Wave Life Sciences stock drops 8% as JPM Healthcare Conference looms; obesity data in focus - TechStock²
Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Wave Life Sciences (WVE) stock slides 6% — what traders are watching next - TechStock²
Wave Life Sciences stock drops 6% as WVE traders size up next obesity data - TechStock²
WAVE Life Sciences (NASDAQ:WVE) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Wave Life Sciences Ltd (WVE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Wave Life Sciences Ltd 주식 (WVE) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Francis Chris | See Remarks |
Jan 02 '26 |
Sale |
16.03 |
9,375 |
150,260 |
25,000 |
| GSK plc | 10% Owner |
Dec 11 '25 |
Buy |
19.00 |
1,470,000 |
27,930,000 |
18,245,691 |
| Rawcliffe Adrian | Director |
Dec 08 '25 |
Option Exercise |
5.97 |
42,000 |
250,740 |
54,700 |
| Rawcliffe Adrian | Director |
Dec 08 '25 |
Sale |
15.00 |
42,000 |
630,000 |
12,700 |
| Wagner Heidi L | Director |
Dec 08 '25 |
Option Exercise |
5.97 |
14,000 |
83,580 |
51,930 |
| Wagner Heidi L | Director |
Dec 08 '25 |
Sale |
13.50 |
14,000 |
189,000 |
44,930 |
| HENRY CHRISTIAN O | Director |
Dec 08 '25 |
Option Exercise |
5.07 |
87,000 |
440,790 |
54,700 |
| HENRY CHRISTIAN O | Director |
Dec 08 '25 |
Sale |
14.65 |
93,445 |
1,369,324 |
12,700 |
| Tan Aik Na | Director |
Dec 08 '25 |
Option Exercise |
4.85 |
119,230 |
578,270 |
70,400 |
| Tan Aik Na | Director |
Dec 08 '25 |
Sale |
13.58 |
134,218 |
1,823,158 |
25,400 |
4.73%
0.92%
자본화:
|
볼륨(24시간):